Clinical Trial Update: RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for RAD001 in relapsed or refractory acute lymphocytic leukemia (ALL) completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphocytic Leukemia

Drugs mentioned

• RAD001 (everolimus)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia, Acute Lymphocytic Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-05-31